Senate BINSA bill by Slotkin & Ricketts targets biotech/pharma deals with China, mirroring House bill amid fierce industry lobbying.
Contentious legislation that would clamp down on biotech and pharma deals in China has been introduced in the Senate, taking the baton from lawmakers in …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing buyers and sellers to rethink…
BINSA, a bipartisan bill restricting US biotech deals with Chinese firms, is in limbo after failing to advance via the House…
US lawmakers push Treasury to screen outbound biotech investments in China under the COINS Act. BINSA bill targets pharmaceutical…
If enacted, BINSA would give lawmakers the right to monitor and restrict American companies from signing biotech and…
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S.…
Bipartisan Michigan lawmakers unveil a bill subjecting US-China biotech deals to outbound investment screening, citing national…
